|
|
Article: BDSI's Phase III Buccal fentanyl data positive.(Thursday, April 26)
- Article from:
- BioWorld Week
- Article date:
- April 30, 2007
CopyrightCOPYRIGHT 2007 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Full results come later, but favorable 30-minute results with Morrisville, N.C.-based BioDelivery Sciences International Inc.'s polymer fentanyl disc in a Phase III study for breakthrough cancer pain sent shares rocketing skyward--and brought BDSI another step closer to taking on Cephalon Inc.'s franchise in the space, where patients are still widely untreated, BDSI said. Shares (NASDAQ:BDSI) gained more than 30 percent April 25 to close at $6.05, up $1.31, after trading as high as $8.26 ...